ORGO

The past six months have seen several events impacting ORGO's stock price, largely influenced by financial results and regulatory changes. Organogenesis reported record net product revenue for fiscal year 2025 and Q4 2025, but also included guidance for an expected near-term revenue decline in 2026. The withdrawal of LCD coverage policies for skin substitutes in December 2025 led to clinician confusion and significant market disruption in Q1 2026. Organogenesis reported a challenging first quarter for 2026, missing both earnings and revenue forecasts, leading to a negative market reaction. Organogenesis completed the rolling submission of its Biologics License Application (BLA) for ReNu to the FDA. A randomized controlled trial for PuraPly AM achieved its primary endpoint of statistically significant diabetic foot ulcer wound closure. Due to the impact on revenue expectations from the prolonged recovery related to regulatory changes, Organogenesis undertook a restructuring in March 2026, including a workforce reduction and facility closure.